PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-BoxA , announced today that, effective July 10, 2015, American Stock Transfer & Trust Company will replace Signature Stock Transfer as its stock transfer and dividend disbursing agent. The Chief Executive Officer of PharmaCyte Biotech, Kenneth L. Waggoner, commented on PharmaCyte Biotech's new stock transfer agent, "We are extremely pleased to announce that we have appointed AST to be our new stock transfer agent.